Home › Compound Library › Vortioxetine (Trintellix)

Vortioxetine (Trintellix)

Antidepressantprescriptionoral · inferred

Multimodal serotonergic antidepressant: SERT inhibition plus 5-HT1A agonism, 5-HT3/5-HT7/5-HT1D antagonism, 5-HT1B partial agonism. Approved for MDD with particular data on cognitive domain (processing speed). 10-20 mg PO daily. Long half-life ~66h. Oral bioavailability ~75%. CYP2D6 primary metabolism; dose-reduce in poor metabolizers / strong inhibitors.

Projected serum levels — 10 mg, once daily

Vortioxetine (Trintellix)
Vortioxetine (Trintellix) modeled serum levels, 10 mg once daily over 22 days Population-based pharmacokinetic estimate. Steady state reached after approximately 8 days. 0 12.5 25 37.5 50 Day 0 Day 6 Day 11 Day 17 Day 22 Time on a regular schedule ≈ steady state · day 8
Vortioxetine (Trintellix) modeled serum levels with a loading dose of 30 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 12.5 25 37.5 50 Day 0 Day 6 Day 11 Day 17 Day 22 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 30 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~8 days: peak ≈ 31.2 mg, trough ≈ 25.9 mg body load. Population-based estimate over 22 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antidepressant
Route modeled
Oral
Model confidence
inferred
Half-life
2.8 days
Common dose
10 mg
Suggested maximum
20 mg/day
Reference dose range
5–20 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.009 mg/L at 7 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Vortioxetine (Trintellix) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Vortioxetine (Trintellix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Vortioxetine (Trintellix) Serotonin risk

    25I-NBOMe and Vortioxetine (Trintellix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Vortioxetine (Trintellix) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Vortioxetine (Trintellix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Vortioxetine (Trintellix) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Vortioxetine (Trintellix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Vortioxetine (Trintellix) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Vortioxetine (Trintellix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Vortioxetine (Trintellix) Serotonin risk

    4-AcO-DMT (Psilacetin) and Vortioxetine (Trintellix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 345 modeled interaction pairings for vortioxetine (trintellix) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Population pharmacokinetic analyses for vortioxetine Areberg J et al. · Clinical Pharmacology in Drug Development, 2014 DOI

    Population PK analysis quantifying vortioxetine's ~66h terminal half-life, ~75% bioavailability, and CYP2D6-dependent clearance variability.

  2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder Thase ME et al. · International Clinical Psychopharmacology, 2016 DOI

    Phase 3 trial demonstrating vortioxetine 10 and 20 mg superior to placebo on MADRS in MDD, with tolerable side-effect profile.

2 published studies referenced in the app, each with a plain-language summary.